Phase II, multicenter, open-label, randomized, controlled, open-label clinical trial to eliminate the latent reservoir of HIV-1 by administration of high doses of antiretroviral drugs.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513366-18-00

Acronym

DOSAGE

Enrollment

Registered

2024-09-09

Start date

2025-04-07

Completion date

Unknown

Last updated

2024-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV infection

Brief summary

- Latent cell reservoir size by measuring total and intact proviral DNA (IPDA).

Interventions

DRUGLamivudina NORMON 300 mg comprimidos recubiertos con película EFG.

DRUGCELSENTRI 300 mg film-coated tablets

DRUGTivicay 50 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
- Latent cell reservoir size by measuring total and intact proviral DNA (IPDA).	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026